02 · Clinical Findings
Staying on a GLP-1 medicine is a clinical question, not just a prescribing number
The company that counted is also the company building a once-a-month alternative, which makes the number true and interested at the same time.
A compilation of 28 studies involving more than 267,000 people with type 2 diabetes found that persistence on GLP-1 medicines declined over time, from 69% at six months to 49% at one year. The studies also differed in how they defined continued treatment.
That pattern matters because trial efficacy and real-world experience answer different questions. A persistence estimate cannot tell why any individual stopped, whether a different medicine would work, or how treatment changes should be managed.
Better comparative studies need to separate cost, access, side effects, supply, and clinical response. The next useful result is an explanation of discontinuation, not simply a lower percentage.
DisclaimerEducational news and research awareness content. Not medical advice.Read full disclaimer ▾
This page shares third-party news coverage, official research listings, and public clinical updates for educational awareness only. Catalyst does not present this information as medical advice, treatment guidance, or a claim of safety, efficacy, or approval.
Related context
How this story connects across the peptide landscape.
Combining two diabetes drug classes is not automatically a bigger clinical benefit
At the highest dose, retatrutide cut 21% of body weight in people with type 2 diabetes
Tirzepatide kept nearly 99% of prediabetes patients diabetes-free over three years
Continue reading · Clinical FindingsPeptide News / Clinical FindingsA small trial found an aging-biomarker signal, not a way to reverse agingUC San Diego Today · Jun 2, 2026 · scroll to read